Jackie Hunter

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Professor Jackie Hunter
Born Ann Jacqueline Hunter[1]
1956 (age 60–61)[2]
Institutions
Alma mater Bedford College, London
Thesis Chemical communication, aggression and sexual behaviour in the owl monkey (Aotus trivirgatus griseimembra) (1981)
Known for
Notable awards
Website
benevolent.ai/blog/

(Ann) Jacqueline Hunter PhD[5] Hons DSc CBE FMedSci FBPharmacolS FRSB FZL is a board director of BenevolentAI and the CEO of its bioscience division BenevolentBio[7] where she directs the application of BenevolentAI’s technology for drug development. Jackie Hunter is also a Professor at St George's Hospital Medical School and was CEO of the Biotechnology and Biological Sciences Research Council.[4][8]

Education[edit]

Jackie Hunter was educated at Selwyn School, Matson, Gloucestershire and at Kings School,[9] Gloucester. She achieved a BSc in Physiology and Psychology at Bedford College, University of London in 1977 and whilst there represented the College on the TV programme University Challenge in 1976. She was awarded her PhD[5] for work carried out at London Zoo entitled ‘Olfaction, aggression and sexual behaviour of owl monkeys (genus Aotus).[5] in 1981.

Career[edit]

Following her PhD, Hunter undertook a Wellcome Trust Postdoctoral research fellowship at St George’s Hospital Medical School before joining the pharmaceutical industry. She worked at Glaxo Laboratories first in Greenford and then Ware on novel therapeutics for Alzheimer’s disease. In 1986 she moved to Astra and then subsequently in 1989 to SmithKline and French just prior to the merger that created SmithKlineBeecham (SB). At SB she held a number of management positions and was responsible for delivering a number of candidate molecules to development as well as large scale external collaborations such as the ENU mutagenesis project with the MRC at Harwell. After the merger between SB and GlaxoWellcome to create GSK, she became head of the Neurology and GI Centre of Excellence for Drug Discovery and Site Head at the GSK site in Harlow, Essex.

In 2008 she developed GSK’s external innovation strategy and was responsible for developing the concept of the Stevenage Bioscience Catalyst and obtaining funding from government and other bodies.

In 2010 she left GSK to establish OI Pharma Partners.[3][4][10][11][12][13][14][15] which was established as a consultancy for the promotion of open innovation in the life sciences, working with governments, academic organisations and companies to formulate open innovation strategies and best practice.

In 2013 she was appointed Chief Executive Officer (CEO) of the BBSRC in 2013.[8][16][17] She has also been a non-executive director of Proximagen group plc and Chiltern International Group (2016–present). She is also a member of the Governing Council of Hertfordshire University.

Awards[edit]

2005 – Honoured by the Academia del Brutium, Rome, for Contributions to Neuroscience

2010 – A winner of the 2010 Women of Achievement in Science, Engineering and Technology (SET) awards in the category SET Discovery, Innovation and Entrepreneurship

2010 – Awarded CBE in Queen’s Birthday Honours list for Services to the Pharmaceutical Industry

2012 – Awarded Fellowship of the British Pharmacological Society (BPS)

2014 – Awarded Fellow of the Academy of Medical Sciences (FMedSci) in 2014.[6] 2014 – Named as one of 50 Movers and Shakers in Bio-Business 2014

2015 – Awarded Fellowship of Zoological Society of London

2015 – Awarded British Pharmacological Society Astra Zeneca prize for Women in Pharmacology

2016 – Awarded Honorary DSc (Brunel University)

2016 – Awarded Fellowship Royal Society of Biology

References[edit]

  1. ^ Jackie Hunter's publications indexed by the Scopus bibliographic database, a service provided by Elsevier. (subscription required)
  2. ^ a b c "Royal Holloway, University of London Dr Jackie Hunter CBE (1956–)". Archived from the original on 2013-11-11. 
  3. ^ a b "OI Pharma Partners – Open Innovation in Healthcare". Archived from the original on 2013-11-08. 
  4. ^ a b c "Chief Executive's biography: Professor Jackie Hunter". Archived from the original on 2013-11-08. 
  5. ^ a b c d Hunter, A. Jackie (1981). Chemical communication, aggression and sexual behaviour in the owl monkey (Aotus trivirgatus griseimembra) (PhD thesis). Bedford College, London. 
  6. ^ a b "New Fellows | The Academy of Medical Sciences". Acmedsci.ac.uk. Retrieved 2017-06-07. 
  7. ^ BenevolentAI. "BenevolentAI | BenevolentAI hires Jackie Hunter as CEO of BenevolentBio". benevolent.ai. Retrieved 2016-12-20. 
  8. ^ a b Jackie Hunter to be next BBSRC chief, Times Higher Education, 2013-06-04
  9. ^ "Jackie Hunter PhD CBE FBPharmacolS LinkedIn profile". Archived from the original on 2013-11-08. 
  10. ^ Hunter, J. (2011). "Challenges for pharmaceutical industry: New partnerships for sustainable human health". Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences. 369 (1942): 1817–1825. Bibcode:2011RSPTA.369.1817H. doi:10.1098/rsta.2010.0377. 
  11. ^ Hagan, J. J.; Leslie, R. A.; Patel, S.; Evans, M. L.; Wattam, T. A.; Holmes, S.; Benham, C. D.; Taylor, S. G.; Routledge, C.; Hemmati, P.; Munton, R. P.; Ashmeade, T. E.; Shah, A. S.; Hatcher, J. P.; Hatcher, P. D.; Jones, D. N.; Smith, M. I.; Piper, D. C.; Hunter, A. J.; Porter, R. A.; Upton, N. (1999). "Orexin a activates locus coeruleus cell firing and increases arousal in the rat". Proceedings of the National Academy of Sciences of the United States of America. 96 (19): 10911–10916. PMC 17982Freely accessible. PMID 10485925. doi:10.1073/pnas.96.19.10911. 
  12. ^ Rogers, D. C.; Fisher, E. M.; Brown, S. D.; Peters, J.; Hunter, A. J.; Martin, J. E. (1997). "Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment". Mammalian genome : official journal of the International Mammalian Genome Society. 8 (10): 711–713. PMID 9321461. doi:10.1007/s003359900551. 
  13. ^ Piper, D. C.; Upton, N.; Smith, M. I.; Hunter, A. J. (2000). "The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats". The European Journal of Neuroscience. 12 (2): 726–730. PMID 10712652. doi:10.1046/j.1460-9568.2000.00919.x. 
  14. ^ Brown, S. D. M.; Peters, P. M.; Strivens, J.; Rogers, M.; Hagan, D.; Spurr, J.; Gray, N.; Vizor, I. C.; Brooker, L.; Whitehill, D.; Washbourne, E.; Hough, R.; Greenaway, T.; Hewitt, S.; Liu, M.; McCormack, X.; Pickford, S.; Selley, K.; Wells, R.; Tymowska-Lalanne, C.; Roby, Z.; Glenister, P.; Thornton, P.; Thaung, C.; Stevenson, C.; Arkell, J. A.; Mburu, R.; Hardisty, P.; Kiernan, R.; Erven, A. (2000). "A systematic, genome-wide, phenotype-driven mutagenesis programme for gene function studies in the mouse". Nature Genetics. 25 (4): 440–443. PMID 10932191. doi:10.1038/78140. 
  15. ^ Piper, D. C.; Upton, N.; Smith, M. I.; Hunter, A. J. (2000). "The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats". European Journal of Neuroscience. 12 (2): 726–730. PMID 10712652. doi:10.1046/j.1460-9568.2000.00919.x. 
  16. ^ "Bioscience innovation leader appointed as next BBSRC Chief Executive". Archived from the original on 2013-11-08. 
  17. ^ "Press release: New chief executive for the Biotechnology and Biological Sciences Research Council". Archived from the original on 2013-11-08. 

External links[edit]

Government offices
Preceded by
Douglas Kell
CEO of the Biotechnology and Biological Sciences Research Council
2013–present
Incumbent